Transfusion-Related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 Trials

Lucia Masarova, Tom Liu, Mirko Fillbrunn, Weilong Li, Gautam Sajeev, Sumati Rao, Boris Gorsh, James Signorovitch, Susan L Slager · 2024

Read Transfusion-Related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 Trials by Lucia Masarova, Tom Liu, Mirko Fillbrunn, Weilong Li, Gautam Sajeev, Sumati Rao, Boris Gorsh, James Signorovitch, Susan L Slager (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11640613.txt.

Description

Nine authors present a cost study from two thousand twenty-four on a drug for a bone marrow disorder. Myelofibrosis often causes anemia, and blood transfusions to treat it burden patients with cost and time. The drug momelotinib was tested against standard care in two large trials, called SIMPLIFY-1 and SIMPLIFY-2.

The authors used the trials' twenty-four-week transfusion data plus cost figures from a United States claims database. They projected how transfusion costs and time would differ on the new drug. Patients were split by whether they needed transfusions at the start, and subgroups by anemia depth and age were checked too.

Catalog record

CREATORLucia Masarova, Tom Liu, Mirko Fillbrunn, Weilong Li, Gautam Sajeev, Sumati Rao, Boris Gorsh, James Signorovitch, Susan L Slager
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11640613

Browse the full library · About the Tower of Babel